Payment overview · 2025
General Payments
$1,185.64
46 reported records · 19 companies
Healthcare provider profile · identity verified
Carlo E Gopez, M.D
Allopathic & Osteopathic Physicians|Family Medicine · ELKTON, MD · NPI 1578770004
Verified facts
What the public records show
CMS Open Payments records show Carlo E Gopez, M.D received $1,185.64 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $324.94 | 27.4% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $150.08 | 12.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $121.45 | 10.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.06 | 7.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.14 | 6.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.26 | 4.7% | 3 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $53.73 | 4.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.96 | 3.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.32 | 3.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.68 | 3.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.15 | 3.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.93 | 2.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.98 | 1.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.81 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.72 | 1.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.91 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.80 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.09 | 1.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $13.63 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,185.64 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $178.77 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $150.08 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $146.17 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $121.45 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.06 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $90.06 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $76.14 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.14 | 4 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $53.73 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $53.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.96 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.01 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.15 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 407 | 111 |
| Lisinopril | Lisinopril | 342 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 254 | 61 |
| Omeprazole | Omeprazole | 235 | 61 |
| Simvastatin | Simvastatin | 211 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 46 |
| Losartan Potassium | Losartan Potassium | 166 | 44 |
| Gabapentin | Gabapentin | 158 | 49 |
| Carvedilol | Carvedilol | 144 | 38 |
| Metformin Hcl | Metformin Hcl | 144 | 37 |
| Prednisone | Prednisone | 139 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 36 |
| Montelukast Sodium | Montelukast Sodium | 138 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 41 |
| Glimepiride | Glimepiride | 105 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 28 |
| Furosemide | Furosemide | 94 | 32 |
| Metformin Hcl Er | Metformin Hcl | 94 | 26 |
| Azithromycin | Azithromycin | 92 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 33 |
| Alprazolam | Alprazolam | 87 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 22 |
| Meloxicam | Meloxicam | 73 | 26 |
| Ibuprofen | Ibuprofen | 71 | 17 |
| Jardiance | Empagliflozin | 70 | 15 |
| Sertraline Hcl | Sertraline Hcl | 70 | 16 |
| Tramadol Hcl | Tramadol Hcl | 69 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 27 |
| Trazodone Hcl | Trazodone Hcl | 62 | 21 |
| Eliquis | Apixaban | 60 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 16 |
| Bupropion Xl | Bupropion Hcl | 54 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Atenolol | Atenolol | 44 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 25 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 31 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 15 |
| Levofloxacin | Levofloxacin | 36 | 26 |
| Allopurinol | Allopurinol | 35 | 11 |
| Celecoxib | Celecoxib | 35 | 13 |
| Famotidine | Famotidine | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 16 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Diazepam | Diazepam | 23 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 11 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,185.64 · 46 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPVAXIVE, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, GARDASIL 9, JARDIANCE, MOUNJARO, NURTEC ODT, NUZYRA, Nimbl, OTEZLA, Omnipod, PROCLAIM, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, Wegovy, XHANCE, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error